HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Multiple Myeloma (MM) Therapies
For multiple myeloma therapies (proteasome inhibitors and immunomodulatory agents), the HFA-ICOS table uses therapy-specific risk factors grouped as Medium¹ (1 […]
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Multiple Myeloma (MM) Therapies Read Post »
Scale